vs
Apellis Pharmaceuticals, Inc.（APLS）与CNA FINANCIAL CORP（CNA）财务数据对比。点击上方公司名可切换其他公司
CNA FINANCIAL CORP的季度营收约是Apellis Pharmaceuticals, Inc.的1.9倍（$389.0M vs $199.9M），CNA FINANCIAL CORP净利率更高（77.6% vs -29.5%，领先107.1%），CNA FINANCIAL CORP同比增速更快（-2.0% vs -5.9%），CNA FINANCIAL CORP自由现金流更多（$542.0M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -2.2%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
CNA金融公司是总部位于美国伊利诺伊州芝加哥的金融企业，旗下核心子公司大陆意外伤害保险公司成立于1897年，大陆保险公司的历史则可追溯至1853年，当前母公司CNA于1967年正式注册成立，在保险及金融服务领域拥有深厚的行业积淀。
APLS vs CNA — 直观对比
营收规模更大
CNA
是对方的1.9倍
$199.9M
营收增速更快
CNA
高出3.9%
-5.9%
净利率更高
CNA
高出107.1%
-29.5%
自由现金流更多
CNA
多$556.3M
$-14.3M
两年增速更快
APLS
近两年复合增速
-2.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $389.0M |
| 净利润 | $-59.0M | $302.0M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 97.2% |
| 净利率 | -29.5% | 77.6% |
| 营收同比 | -5.9% | -2.0% |
| 净利润同比 | -62.2% | 1338.1% |
| 每股收益（稀释后） | $-0.40 | $1.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSCNA
| Q4 25 | $199.9M | $389.0M | ||
| Q3 25 | $458.6M | $393.0M | ||
| Q2 25 | $178.5M | $398.0M | ||
| Q1 25 | $166.8M | $397.0M | ||
| Q4 24 | $212.5M | $397.0M | ||
| Q3 24 | $196.8M | $401.0M | ||
| Q2 24 | $199.7M | $404.0M | ||
| Q1 24 | $172.3M | $407.0M |
净利润APLSCNA
| Q4 25 | $-59.0M | $302.0M | ||
| Q3 25 | $215.7M | $403.0M | ||
| Q2 25 | $-42.2M | $299.0M | ||
| Q1 25 | $-92.2M | $274.0M | ||
| Q4 24 | $-36.4M | $21.0M | ||
| Q3 24 | $-57.4M | $283.0M | ||
| Q2 24 | $-37.7M | $317.0M | ||
| Q1 24 | $-66.4M | $338.0M |
营业利润率APLSCNA
| Q4 25 | -25.6% | 97.2% | ||
| Q3 25 | 48.7% | — | ||
| Q2 25 | -18.6% | 95.5% | ||
| Q1 25 | -50.0% | 87.9% | ||
| Q4 24 | -12.3% | 5.3% | ||
| Q3 24 | -24.0% | 90.0% | ||
| Q2 24 | -14.7% | 99.5% | ||
| Q1 24 | -36.0% | — |
净利率APLSCNA
| Q4 25 | -29.5% | 77.6% | ||
| Q3 25 | 47.0% | 102.5% | ||
| Q2 25 | -23.6% | 75.1% | ||
| Q1 25 | -55.3% | 69.0% | ||
| Q4 24 | -17.1% | 5.3% | ||
| Q3 24 | -29.2% | 70.6% | ||
| Q2 24 | -18.9% | 78.5% | ||
| Q1 24 | -38.5% | 83.0% |
每股收益（稀释后）APLSCNA
| Q4 25 | $-0.40 | $1.11 | ||
| Q3 25 | $1.67 | $1.48 | ||
| Q2 25 | $-0.33 | $1.10 | ||
| Q1 25 | $-0.74 | $1.00 | ||
| Q4 24 | $-0.30 | $0.07 | ||
| Q3 24 | $-0.46 | $1.04 | ||
| Q2 24 | $-0.30 | $1.17 | ||
| Q1 24 | $-0.54 | $1.24 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | — |
| 总债务越低越好 | — | $3.0B |
| 股东权益账面价值 | $370.1M | $11.6B |
| 总资产 | $1.1B | $69.4B |
| 负债/权益比越低杠杆越低 | — | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资APLSCNA
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | — | ||
| Q1 24 | $325.9M | — |
总债务APLSCNA
| Q4 25 | — | $3.0B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $3.0B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSCNA
| Q4 25 | $370.1M | $11.6B | ||
| Q3 25 | $401.2M | $11.3B | ||
| Q2 25 | $156.3M | $10.7B | ||
| Q1 25 | $164.2M | $10.3B | ||
| Q4 24 | $228.5M | $10.5B | ||
| Q3 24 | $237.1M | $10.8B | ||
| Q2 24 | $264.3M | $9.9B | ||
| Q1 24 | $266.7M | $9.7B |
总资产APLSCNA
| Q4 25 | $1.1B | $69.4B | ||
| Q3 25 | $1.1B | $69.8B | ||
| Q2 25 | $821.4M | $68.9B | ||
| Q1 25 | $807.3M | $67.3B | ||
| Q4 24 | $885.1M | $66.5B | ||
| Q3 24 | $901.9M | $67.4B | ||
| Q2 24 | $904.5M | $65.2B | ||
| Q1 24 | $831.9M | $65.1B |
负债/权益比APLSCNA
| Q4 25 | — | 0.26× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.28× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $570.0M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $542.0M |
| 自由现金流率自由现金流/营收 | -7.1% | 139.3% |
| 资本支出强度资本支出/营收 | 0.1% | 7.2% |
| 现金转化率经营现金流/净利润 | — | 1.89× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $2.4B |
8季度趋势，按日历期对齐
经营现金流APLSCNA
| Q4 25 | $-14.2M | $570.0M | ||
| Q3 25 | $108.5M | $720.0M | ||
| Q2 25 | $4.4M | $562.0M | ||
| Q1 25 | $-53.4M | $638.0M | ||
| Q4 24 | $19.4M | $703.0M | ||
| Q3 24 | $34.1M | $748.0M | ||
| Q2 24 | $-8.3M | $616.0M | ||
| Q1 24 | $-133.0M | $504.0M |
自由现金流APLSCNA
| Q4 25 | $-14.3M | $542.0M | ||
| Q3 25 | $108.3M | $704.0M | ||
| Q2 25 | $4.4M | $538.0M | ||
| Q1 25 | $-53.4M | $620.0M | ||
| Q4 24 | $19.3M | $665.0M | ||
| Q3 24 | — | $730.0M | ||
| Q2 24 | $-8.4M | $597.0M | ||
| Q1 24 | $-133.3M | $484.0M |
自由现金流率APLSCNA
| Q4 25 | -7.1% | 139.3% | ||
| Q3 25 | 23.6% | 179.1% | ||
| Q2 25 | 2.5% | 135.2% | ||
| Q1 25 | -32.0% | 156.2% | ||
| Q4 24 | 9.1% | 167.5% | ||
| Q3 24 | — | 182.0% | ||
| Q2 24 | -4.2% | 147.8% | ||
| Q1 24 | -77.3% | 118.9% |
资本支出强度APLSCNA
| Q4 25 | 0.1% | 7.2% | ||
| Q3 25 | 0.0% | 4.1% | ||
| Q2 25 | 0.0% | 6.0% | ||
| Q1 25 | 0.0% | 4.5% | ||
| Q4 24 | 0.0% | 9.6% | ||
| Q3 24 | 0.0% | 4.5% | ||
| Q2 24 | 0.0% | 4.7% | ||
| Q1 24 | 0.2% | 4.9% |
现金转化率APLSCNA
| Q4 25 | — | 1.89× | ||
| Q3 25 | 0.50× | 1.79× | ||
| Q2 25 | — | 1.88× | ||
| Q1 25 | — | 2.33× | ||
| Q4 24 | — | 33.48× | ||
| Q3 24 | — | 2.64× | ||
| Q2 24 | — | 1.94× | ||
| Q1 24 | — | 1.49× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
CNA
暂无分部数据
